Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.
Clinical trial NCT01918878 · UNKNOWN
Trial details
- NCT number
- NCT01918878
- Sponsor
- Hadassah Medical Organization
- Status
- UNKNOWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2013-10-01
- Primary completion
- 2016-04-01
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.